389 related articles for article (PubMed ID: 30373917)
21. Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer.
Bhateja P; Chiu M; Wildey G; Lipka MB; Fu P; Yang MCL; Ardeshir-Larijani F; Sharma N; Dowlati A
Cancer Med; 2019 Apr; 8(4):1459-1466. PubMed ID: 30773851
[TBL] [Abstract][Full Text] [Related]
22. Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation.
Fiorentino FP; Tokgün E; Solé-Sánchez S; Giampaolo S; Tokgün O; Jauset T; Kohno T; Perucho M; Soucek L; Yokota J
Oncotarget; 2016 May; 7(21):31014-28. PubMed ID: 27105536
[TBL] [Abstract][Full Text] [Related]
23. Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer.
Alcaraz-Sanabria A; Nieto-Jiménez C; Corrales-Sánchez V; Serrano-Oviedo L; Andrés-Pretel F; Montero JC; Burgos M; Llopis J; Galán-Moya EM; Pandiella A; Ocaña A
Mol Cancer Ther; 2017 Nov; 16(11):2552-2562. PubMed ID: 28847989
[TBL] [Abstract][Full Text] [Related]
24. Trametinib downregulates survivin expression in RB1-positive KRAS-mutant lung adenocarcinoma cells.
Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Niki T; Takahashi H; Sakuma Y
Biochem Biophys Res Commun; 2018 Jun; 501(1):253-258. PubMed ID: 29727601
[TBL] [Abstract][Full Text] [Related]
25. A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells.
Bulanova D; Akimov Y; Senkowski W; Oikkonen J; Gall-Mas L; Timonen S; Elmadani M; Hynninen J; Hautaniemi S; Aittokallio T; Wennerberg K
Sci Adv; 2024 May; 10(21):eadj1564. PubMed ID: 38781347
[TBL] [Abstract][Full Text] [Related]
26. Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer.
Liu JC; Granieri L; Shrestha M; Wang DY; Vorobieva I; Rubie EA; Jones R; Ju Y; Pellecchia G; Jiang Z; Palmerini CA; Ben-David Y; Egan SE; Woodgett JR; Bader GD; Datti A; Zacksenhaus E
Cell Rep; 2018 Apr; 23(1):112-126. PubMed ID: 29617654
[TBL] [Abstract][Full Text] [Related]
27. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
Dauch D; Rudalska R; Cossa G; Nault JC; Kang TW; Wuestefeld T; Hohmeyer A; Imbeaud S; Yevsa T; Hoenicke L; Pantsar T; Bozko P; Malek NP; Longerich T; Laufer S; Poso A; Zucman-Rossi J; Eilers M; Zender L
Nat Med; 2016 Jul; 22(7):744-53. PubMed ID: 27213815
[TBL] [Abstract][Full Text] [Related]
28.
Fang Z; Wang Y; Wang Z; Xu M; Ren S; Yang D; Hong M; Xie W
Cancer Res; 2020 Oct; 80(20):4399-4413. PubMed ID: 32826278
[TBL] [Abstract][Full Text] [Related]
29. Treatment of RB-deficient retinoblastoma with Aurora-A kinase inhibitor.
Yang W; Jiang XX; Zhao XY; Mao PA
Kaohsiung J Med Sci; 2022 Mar; 38(3):244-252. PubMed ID: 34741392
[TBL] [Abstract][Full Text] [Related]
30. Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy.
Knudsen ES; Pruitt SC; Hershberger PA; Witkiewicz AK; Goodrich DW
Trends Cancer; 2019 May; 5(5):308-324. PubMed ID: 31174843
[TBL] [Abstract][Full Text] [Related]
31. Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer.
Brough R; Gulati A; Haider S; Kumar R; Campbell J; Knudsen E; Pettitt SJ; Ryan CJ; Lord CJ
Oncogene; 2018 Oct; 37(43):5701-5718. PubMed ID: 29915391
[TBL] [Abstract][Full Text] [Related]
32. Spindle assembly checkpoint gene expression in childhood adrenocortical tumors (ACT): Overexpression of Aurora kinases A and B is associated with a poor prognosis.
Borges KS; Moreno DA; Martinelli CE; Antonini SR; de Castro M; Tucci S; Neder L; Ramalho LN; Seidinger AL; Cardinalli I; Mastellaro MJ; Yunes JA; Brandalise SR; Tone LG; Scrideli CA
Pediatr Blood Cancer; 2013 Nov; 60(11):1809-16. PubMed ID: 23788275
[TBL] [Abstract][Full Text] [Related]
33. Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells.
Wu C; Lyu J; Yang EJ; Liu Y; Zhang B; Shim JS
Nat Commun; 2018 Aug; 9(1):3212. PubMed ID: 30097580
[TBL] [Abstract][Full Text] [Related]
34. Knocking down the expression of Aurora-A gene inhibits cell proliferation and induces G2/M phase arrest in human small cell lung cancer cells.
Lu Y; Liu Y; Jiang J; Xi Z; Zhong N; Shi S; Wang J; Wei X
Oncol Rep; 2014 Jul; 32(1):243-9. PubMed ID: 24841948
[TBL] [Abstract][Full Text] [Related]
35. Quantitative Proteomics Reveals That the Inhibition of Na(+)/K(+)-ATPase Activity Affects S-Phase Progression Leading to a Chromosome Segregation Disorder by Attenuating the Aurora A Function in Hepatocellular Carcinoma Cells.
Xu Z; Wang F; Fan F; Gu Y; Shan N; Meng X; Cheng S; Liu Y; Wang C; Song Y; Xu R
J Proteome Res; 2015 Nov; 14(11):4594-602. PubMed ID: 26491887
[TBL] [Abstract][Full Text] [Related]
36. Silencing Aurora-A with siRNA inhibits cell proliferation in human lung adenocarcinoma cells.
Zhong N; Shi S; Wang H; Wu G; Wang Y; Ma Q; Wang H; Liu Y; Wang J
Int J Oncol; 2016 Sep; 49(3):1028-38. PubMed ID: 27571708
[TBL] [Abstract][Full Text] [Related]
37. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Wang NJ; Zhao RJ; Zhou SF
Drug Des Devel Ther; 2015; 9():487-508. PubMed ID: 25609923
[TBL] [Abstract][Full Text] [Related]
39. Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases.
Matsuhashi A; Ohno T; Kimura M; Hara A; Saio M; Nagano A; Kawai G; Saitou M; Takigami I; Yamada K; Okano Y; Shimizu K
Curr Cancer Drug Targets; 2012 Jul; 12(6):625-39. PubMed ID: 22463590
[TBL] [Abstract][Full Text] [Related]
40. An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor.
Durlacher CT; Li ZL; Chen XW; He ZX; Zhou SF
Clin Exp Pharmacol Physiol; 2016 Jun; 43(6):585-601. PubMed ID: 26999067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
